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The Regulator of G protein signaling 4 (RGS4) gene is a candidate susceptibility gene for 
schizophrenia (SCZ). Previous studies showed that the mRNA level of the longest splice 
variant RGS4-1 was decreased in the dorsolateral prefrontal cortex (DLPFC) of SCZ 
patients compared with healthy controls. In this pilot study, we examined the possible 
mechanisms of RGS4-1 mRNA reduction in SCZ. We genotyped SNP1 (rs10917670), 
rs2661347, SNP4 (rs951436), SNP7 (rs951439), SNP18 (rs2661319), and rs10799897 
(SNP9897) and tested the methylation status of CpG islands of the RGS4 gene in the 
postmortem DLPFC samples obtained from subjects with SCZ and bipolar disorder as 
well as healthy controls. RGS4-1 mRNA level was associated with five SNPs (SNP1, 
rs2661347, SNP4, SNP7, and SNP18) and their haplotypes but not with SNP9897. 
In addition, this study revealed that RGS4-1 mRNA was low in subjects with specific 
genotypes of SNP1, rs2661347, SNP4, SNP7, and SNP18. Lower RGS4-1 mRNA 
expression in the DLPFC of SCZ is associated with SNPs in the 5′ regulatory region of 
the RGS4 gene but not with the methylation status of its CpG islands.
Keywords: genotype, bipolar disorder, psychiatric, allele, postmortem, regulatory region
inTrODUcTiOn
The Regulator of G protein signaling 4 (RGS4) gene is associated with susceptibility to schizophrenia 
(SCZ). A previous microarray study showed that RGS4 mRNA levels were decreased in prefrontal 
cortex (PFC) of SCZ patients as compared to healthy subjects (1). The four common single-nucleotide 
polymorphisms (SNP1, 4, 7, and 18) of the RGS4 gene, localized between the 5′ upstream sequence 
and the second intron, as well as two haplotypes derived from these SNPs may confer SCZ risk 
(2). Some other SNPs in the 20 kb genomic region of RGS4 are associated with SCZ (2), and the 
G-allele of SNP1 is associated with non-deficit SCZ (3). Other linkage and association studies also 
indicated a connection between RGS4 polymorphisms and SCZ risk (4–6). RGS4 polymorphisms 
(SNP1, 4, 7, and 18) were associated with differences in the dorsolateral prefrontal cortex (DLPFC) 
volume in first episode SCZ patients (7). Several RGS4 SNPs are associated with clinical symptoms 
of SCZ. For example, Positive and Negative Symptoms Scale (PANSS) total and global psychopa-
thology scores were associated with SNP4 (8). SNP18 (rs2661319) and rs2842030 were associated 
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with more severe baseline PANSS total score (9). At the baseline 
status, the A/A genotype at SNP7 of RGS4 was associated with 
a poorer social function compared with the G/G genotype (10). 
SNP1 (rs10917670) was associated with the depression factor in 
SCZ (11).
We previously cloned five splice variants of RGS4 mRNA 
expressed in the DLPFC of the human brain and three splice 
variants of Rgs4 from the mouse brain and found that the 
transcriptional regulation of human RGS4 differs from that 
of the mouse Rgs4. Our data showed that mouse Rgs4 encodes 
one protein while human RGS4 encodes four different proteins, 
three of which are unique to humans (12). We also found that 
the mRNA level of the longest isoform RGS4-3 was specifically 
deceased in DLPFC of SCZ patients but not in healthy controls 
(NC) or subjects with bipolar disorder (BPD) (13). Since then, 
RGS4-3 has been renamed RGS4-1 (NM_001102445.2), and we 
use the new nomenclature here.
How is RGS4-1 decreased in DLPFC of SCZ? One possibility is 
through epigenetic regulatory mechanisms such as DNA hyper-
methylation. Bioinfomatics analysis found CpG islands (GC% 
>50%, >200 bp and the ratio of observed/expected CpG >0.6) 
(14) spanning 246 bp located in the first intron and second exon of 
the RGS4 gene. Hypermethylation of CpG islands leads to decrease 
in gene expression (15, 16), which might explain the reduction 
in RGS4-1 mRNA level. To test whether the decrease in RGS4-1 
mRNA expression in the DLPFC of postmortem SCZ brains is 
due to epigenetic mechanisms, such as DNA hypermethylation, 
we investigated the methylation status of CpG islands of RGS4.
RGS4-1 might also be decreased through mechanisms in 
which the regulatory region of the RGS4 gene plays a role. Such 
a possibility might be revealed by testing whether the SNPs in 
the regulatory region of the RGS4 gene are associated with RGS4 
mRNA expression. Therefore, we genotyped a few SNPs in the 
regulatory region of the RGS4 gene including SNP1 (rs10917670), 
rs2661347, SNP4 (rs951436), SNP7 (rs951439), SNP18 
(rs2661319), and rs10799897 (SNP9897) to test for possible 
associations between the SNPs and RGS4 mRNA expression. We 
present results showing that expression of RGS4-1 is associated 
with five SNPs and that RGS4-1 expression is not correlated with 
the methylation status of CpG islands in the RGS4 gene.
MaTerials anD MeThODs
rna and Dna samples
RNA samples (RNA Array Collection) from the DLPFC of post-
mortem brains of the patients with SCZ, BPD, and normal controls 
(NC) (N = 35 in each group) were obtained from Stanly Medical 
Research Institute (SMRI) (see Tables S1 and S2 in Supplementary 
Material for demographic and other details), and mRNA expres-
sion levels in these samples were measured by quantitative real-
time PCR (qPCR) (13). The corresponding DNA samples from 
the DLPFC and occipital cortex from the postmortem brains of 
these patients and NC were also obtained from SMRI.
The samples used in this study were all from post-mortem 
brain tissue, and therefore a protocol approved by the Institutional 
Review Board was not necessary as per institutional guidelines.
snP genotyping assays and haplotype 
Determination
We used pre-designed Taqman SNP genotyping assays for 
SNP18 (rs2661319) and SNP9897 from Applied Biosystems 
(AB). Custom Taqman SNP genotyping assays for SNP4 
(rs951436) and SNP7 (rs951439) (Table S3 in Supplementary 
Material) were designed using AB web site.1 We chose these 
SNPs because of their known association with SCZ. All the four 
SNPs were identified at the Genotyping Core of University of 
North Carolina (UNC) Chapel Hill. To verify the genotyping 
accuracy, 12 randomly selected samples were also genotyped 
again by Roche Light Cycler 480 using the same TaqMan assays. 
The two genotyping results completely match. Primers and 
probe sequences used for genotyping are shown in Table S4 in 
Supplementary Material. SNP1 (rs10917670) was identified by 
PCR and sequencing since it did not comply with the ABI cus-
tom Taqman assay design requirement. All analyses were car-
ried out blind with respect to diagnosis. Haploview 4.2 (Broad 
Institute of MIT and Harvard)2 was used to perform Linkage 
Disequilibrium (LD) analysis. Based on population genotype, 
the program PHASE3 was used to reconstruct haplotype and 
assign diplotype for each individual and calculate haplotype 
frequency (17).
Bioinformatics analysis, Primer Design, 
and Dna Methylation analysis
To identify possible CpG islands in the regulatory region and 
introns of the RGS4 gene, a 3.2-kb putative promoter region 
including the 5′ regulatory region upstream of the transcription 
start site (TSS), exon1, 2 and intron 1 of RGS4 were searched, and 
a 246 bp region containing nine CpG islands was found. The 105 
DNA samples from SMRI were treated with bisulfite, and then 
used for PCR amplification and PCR products sequencing (18). 
Briefly, 125 ng of DNA was treated by bisulfite using EZ DNA 
methylation kit (Zymo Research Corporation, Irvine, CA, USA). 
Human Methylated and Non-Methylated DNA Set (Human 
HCT116 DKO Methylated and non-methylated DNAs) were used 
as positive and negative controls (Zymo Research Corporation). 
The bisulfite PCR primers for DNA methylation analysis of RGS4 
were designed by using MethPrimer.4
The primers were: RGS4-BSP_fd 5′ TAGAGGGAGATAGA 
GGAGTTGGTATT 3′ and RGS4-BSP_rev 5′ ACAAACCTACAA 
ACCCTTTACACAT3′. ZymoTaq™ DNA Polymerase was used 
to amplify bisulfite-treated DNA.
statistical analysis
SAS software 9.2 (SAS Institute Inc., Cary, NC, USA) was used 
to perform statistical analysis. Pearson’s Correlation analysis 
was performed to identify possible correlations between the 
1 https://www5.appliedbiosystems.com/tools/cadt/
2 http://www.broadinstitute.org/scientific-community/science/programs/
medical-and-population-genetics/haploview/haploview
3 http://stephenslab.uchicago.edu/software.html
4 http://www.urogene.org/
FigUre 1 | location of snPs in the RGS4 gene. SNP1, SNP4, and SNP7 are located in the 5′ regulatory region of RGS4. SNP18 is in the second intron and 
SNP9897 is in the fourth intron of the RGS4 gene.
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mRNA expression levels of two different splice variants. The 
association analysis of SNPs with SCZ or BPD was performed 
by using Haploview and PROC LOGISTIC regression analysis in 
the SAS software. The general linear model was used to analyze 
the relationship of the mRNA expression level with SNPs by 
using SAS software. When analyzing the association of genotypes 
with mRNA expression level of RGS4 splice variants, an addi-
tive model was used, in which the phenotype of heterozygotes 
is intermediate to those of the two homozygotes. Previously, we 
found that the mRNA expression level of RGS4-1 was significantly 
decreased in the DLPFC of SCZ compared to normal controls and 
was correlated with brain weight, and mRNA expression level of 
RGS4-2 was correlated with brain pH (13). We did not, however, 
find a correlation between mRNA expression of RGS4 isoforms 
and RNA integrity number (RIN), age, gender, postmortem 
interval, race, refrigerator interval, age of onset and duration of 
illness, lifetime use of alcohol, or antipsychotics. Therefore, to 
compare the effect of genotype or diplotype on mRNA level of 
RGS4-1 in among all groups (including SCZ, NC, and BP groups), 
univariate analysis of covariance (ANCOVA) was performed, in 
which mRNA expression of RGS4-1 or RGS4-2 was a dependent 
variable, while genotype or diplotype was used as an independ-
ent factor and brain weight or brain pH as a covariate. To detect 
a possible interaction between SNP genotype and groups, SNP 
genotype and group were taken as two factors, and brain weight 
as a covariate.
When analyzing the relationship of SNPs with mRNA 
expression level of RGS4-1 between groups, group (SCZ, 
BPD, or NC) was an independent variable, brain weight was a 
covariate, and post hoc test was used to identify the differences 
in RGS4-1 mRNA levels between different groups. To determine 
the possible differences in the ratio between two splice variants 
among groups, general linear model was used, with the ratio as a 
dependent factor and the group as independent variable. To test 
whether the SNPs were related to ratios, the ratio was taken as 
a dependent variable and the genotype of SNPs and group were 
two factorial independent variables. Then post  hoc Bonferroni 
test was applied.
resUlTs
association of mrna expression of rgs4 
splice Variants with rgs4 snPs
Although we successfully genotyped six SNPs in the 5′ regula-
tory region and introns of RGS4 in all samples from SMRI (see 
Table S1 in Supplementary Material for demographics), some 
RNA samples had to be excluded because of insufficient quantity 
and other limitations (reasons for which are detailed under 
Table S2 in Supplementary Material). Therefore, statistical analy-
sis of the association between SNPs and the mRNA expression 
levels of RGS4 splice variants was performed on samples from 
27 individuals in each group (13). All DNA samples were from 
Caucasian subjects except for one from a Hispanic subject in 
the SCZ group and another from a Native American subject 
in the BPD group. Regardless of whether these two cases were 
included or not in the analysis, the statistical outcome remained 
the same. The mRNA expression levels of the isoforms RGS4-2 to 
RGS4-5 were not associated (p > 0.05) with the six SNPs of the 
RGS4 gene that we examined. However, the mRNA expression 
of the longest isoform RGS4-1 was associated with the five SNPs 
(SNP1, rs2661347, SNP4, SNP7 and SNP18, p < 0.05) but not with 
SNP9897 (p > 0.05).
When the three groups were considered together including 
all samples from SCZ, normal controls (NC), and BPD, RGS4-1 
mRNA expression level was associated with the genotype of SNP1 
[F(3,77) = 4.20, overall p = 0.0083, SNP1 genotype p = 0.0263] 
and rs2661347 [F(3,77) =  4.69, overall p =  0.0046, rs2661347 
genotype p = 0.0141]. The mRNA expression levels of RGS4-1 in 
the carriers with homozygous genotype TT of SNP1 or with allele 
T of SNP1 were lower than that from subjects with genotype CC 
(adjusted p = 0.0220) or allele C of SNP1 (adjusted p = 0.0338). 
The genotype TT of rs2661347 or allele T of rs2661347 was 
associated with lower amounts of RGS4-1 transcript compared 
with genotype AA of rs2661347 (p  =  0.0117) (Figure  2) or 
allele A (p = 0.0106). RGS4-1 mRNA expression level was also 
associated with the genotype of SNP4 [F(3,77) =  4.93, overall 
p = 0.0035, SNP4 genotype p = 0.0104], SNP7 [F (3,77) = 4.20, 
FigUre 2 | effects of snP1 and rs2661347 on RGS4-1 mrna expression levels. RGS4-1 mRNA expression level in genotype TT of SNP1 was significantly 
lower than that of the genotype CC [F(3,77) = 4.20, overall p = 0.0083, SNP1 genotype p = 0.0263] (a). The genotype TT of rs2661347 had significantly lower 
expression level of RGS4-1 mRNA compared to the genotype AA [F(3,77) = 4.69, overall p = 0.0046, rs2661347 genotype p = 0.0141] (B).
FigUre 3 | effects of snP1 and rs2661347 genotypes on RGS4-1 mrna expression among the groups. In the schizophrenia group (SCZ), the RGS4-1 
mRNA expression level in the subjects with genotype CC of SNP1 were lower than the people in the normal control (NC) group with same genotype CC (adjusted 
p = 0.0324) of SNP1 (a). In the SCZ group, the patients with the genotype AA of rs2661347 ( p = 0.0984) tended to have lower mRNA expression than those with 
the same genotype in the NC group (B). Boxes represent 25th and 75th percentile distribution. Bars outside the box represent the SD.
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FigUre 4 | association of RGS4-1 mrna expression levels with the genotypes of snP4 and snP7. The genotype AA of SNP4 was associated with the 
lower expression level of RGS4-1, and CC was related with the higher expression of RGS4-1 [F(3,77) = 4.93, overall p = 0.0035, SNP4 genotype p = 0.0104] (a). 
The genotype TT of SNP7 was associated with the lower expression level, and CC with higher expression level of RGS4-1 [F(3,77) = 4.20, overall p = 0.0083, SNP7 
genotype p = 0.0263] (B).
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overall p  =  0.0083, SNP7 genotype p  =  0.0263], and SNP18 
[F (3,77) = 3.86 overall p = 0.0126, SNP18 genotype p = 0.0413]. 
The genotype AA or allele A of SNP4 had lower mRNA of RGS4-1 
compared to TT (p = 0.0081) or allele T (p = 0.0106) (Figure 4). 
The genotype TT (p = 0.0220) or allele T (p = 0.0338) of SNP7 
(Figure 4) and genotype AA (p = 0.0401) or allele A (p = 0.0267) 
of SNP18 were associated with lower RGS4-1 mRNA expression 
level compared to CC or allele C of SNP7, or GG or G of SNP18 
(Figure 6).
In addition, in the univariate ANCOVA model to find the 
risk factors for decreased RGS4-1 mRNA level, the interaction 
of SNP18 genotype ×  group (SCZ/BPD/NC) was statistically 
significant (p < 0.05) and the interaction of rs2661347 and SNP4 
with group was close to statistical significance. The p-values for 
interaction between the group and SNP1, rs2661347, SNP4, 
SNP7, or SNP18 were 0.1698, 0.0588, 0.0549, 0.1698, and 
0.0347, respectively. When we compared the effects of these 
genotypes on the RGS4-1 mRNA levels between groups, we 
found that in the SCZ group, the genotype CC of SNP1 was 
related to the lower expression level of RGS4-1 in the DLPFC 
compared to the NC group (p =  0.0385, Figure  3). In SCZ, 
the subjects with the genotype AA of rs2661347 (p = 0.0984) 
or genotype CC of SNP4 (p  =  0.0984) tend to have lower 
RGS4-1 mRNA expression level in the DLPFC than those with 
the same genotype in the NC group (Figures 3 and 5). In the 
SCZ group, the samples from patients with genotype CC of 
SNP7 (p = 0.0373) or the genotype GG of SNP18 (p = 0.0393) 
were associated with lower mRNA expression level of RGS4-1 
in the DLPFC than the subjects with the same genotype in the 
NC group (Figures 5 and 6).
To test whether expression of a given RGS4 isoform is 
positively or negatively correlated with the expression of 
other RGS4 isoforms, Pearson correlation analyses were per-
formed, which showed that among different RGS4 splice vari-
ants only the mRNA level of RGS4-4 was positively correlated 
with that of RGS4-5. When mRNA expression of all RGS4 
isoforms were quantified collectively using a set of primers 
that detect all five RGS4 isoforms [referred to as Pan-RGS4 
in our previous study (13)] as expected, we found that Pan-
RGS4 expression was positively correlated with expression of 
all RGS4 isoforms.
linkage Disequilibrium analysis of snPs 
and the haplotypes of rgs4 snPs
We carried out linkage disequilibrium (LD) analysis of RGS4 
SNPs SNP1, rs2661347, SNP4, SNP7, rs2661319, and SNP9897 
in all subjects including the SCZ, NC, and BPD groups. We 
found that SNP1, rs2661347, SNP4, and SNP7, were in dis-
equilibrium with each other and were haplotype tagging SNPs 
(Figure 8).
The constructed haplotypes and their frequencies obtained 
from the program PHASE in the three groups are shown in Table 
S5 in Supplementary Material. There are five haplotypes; the most 
common haplotype is hap1 (CACCG), and the second frequent 
one is hap4 (TTATA).
association between haplotypes of rgs4 
snPs and the mrna expression of rgs4 
splice Variants
The haplotypes of RGS4 SNPs were not associated with the 
mRNA expression of RGS4-2, RGS4-3, RGS4-4, and RGS4-5. 
However, when all the groups were analyzed together as a 
whole, the diplotype (Hap1/Hap1) was associated with higher 
RGS4-1 mRNA expression level, and Non-Hap1 diplotypes 
(Hap2Hap2, Hap2Hap3, Hap4Hap4, and Hap4Hap5) were 
associated with lower RGS4-1 mRNA expression level 
[F(3,77) =  4.69 overall p =  0.0046, haplotype p =  0.0141]. 
Non-Hap1 carriers had lower RGS4-1 mRNA expression 
level (p =  0.0117). In the SCZ group, Non-Hap4 diplotype 
FigUre 5 | effects of snP4 and snP7 genotypes on RGS4-1 mrna expression among the groups. (a). In the schizophrenia (SCZ) group, the 
subjects with genotype CC of SNP4 tended to have lower mRNA expression level of RGS4-1 than the subjects with the same genotype CC of SNP4 in NC 
( p = 0.0984) (B). The mRNA of RGS4-1 in SCZ patients with genotype CC of SNP7 was lower than those of the individuals with the same genotype CC in NC 
( p = 0.0373).
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(Hap1Hap2, Hap1Hap5, Hap2Hap2, Hap1Hap1, Hap2Hap3) 
or Non-Hap4 carrier had lower RGS4-1 mRNA expression level 
compared to NC [F(3,32) =  3.57, overall p =  0.0246, Group 
p = 0.0171] (Figure 7).
altered ratio of rgs4 splice Variants in 
scZ and BPD
Changes in ratios between splice variants could contribute to 
the development of some diseases. For example, in sporadic 
colorectal cancer, the ratio of splice variants K-ras 4A and 4B is 
altered (19). To examine whether the ratio of RGS4 splice vari-
ants changes in the DLPFC of SCZ or BPD, the ratio between 
two splice variants (ratio 1 to 2) was calculated using the for-
mula 2(Ct2 − Ct1) where Ct1 is threshold Ct value of splice variant 
1, and Ct2 is threshold Ct value of splice variant 2 as measured 
by qPCR. The ratio of the mRNA expression level of RGS4-1 to 
RGS4-3 were different among groups [F(2,78) =  3.78, overall 
p = 0.0270]. The ratio decreased in SCZ (mean ratio = 0.0310) 
compared to NC (mean ratio  =  0.0525) (p  =  0.0237). The 
ratios of RGS4-1 to other isoforms were not significantly 
different (p >  0.05). The ratio of mRNA expression level of 
RGS4-2 and RGS4-3 decreased in BPD (mean ratio = 0.0048) 
compared to NC (mean ratio = 0.0069) [F(2,78) = 4.58, overall 
p =  0.0131, p =  0.0114 between BPD and NC]. The ratio of 
mRNA expression level of RGS4-2 to RGS4-5 was different 
among the three groups [F(2,78) =  4.38, overall p =  0.0157]. 
Pairwise comparison test indicated that the ratio of RGS4-2 to 
RGS4-5 decreased in BPD (mean ratio = 5.63) compared to NC 
(mean ration = 8.81) (p = 0.0321), or compared to SCZ (mean 
ratio = 8.69) (p = 0.0426). The ratios of mRNA expression level 
of RGS4-2 to other isoforms were not different. None of the 
SNPs was found to be associated with any ratio change of RGS4 
transcripts.
FigUre 6 | effects of snP18 genotypes on RGS4-1mrna expression. (a) Among all the groups, the individuals with the genotype AA of SNP18 had lower 
mRNA expression of RGS4-1 compared with the subjects with genotype GG of SNP18 [F (3,77) = 3.86 overall p = 0.0126; SNP18 genotype p = 0.0413]. (B) In 
SCZ, the subjects with genotype GG of SNP18 had lower mRNA expression level of RGS4-1 compared with the subjects with the same genotype GG of SNP18 in 
NC ( p = 0.0393).
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snP rs2661347 genotype and allele 
Frequency
Even though there have been detailed studies of RGS4 SNPs 1, 
4, 7, and 18 with respect to genotype and allele frequency, SNP 
rs2661347 is less well studied. Therefore, we calculated genotype 
and allele frequency of rs2661347 in 35 normal control Caucasian 
subjects from SMRI. The major allele (A) frequency is 0.557 
(39/70), the frequency of minor allele (T) is 0.443 (31/70). The 
genotype frequency is A/A (0.343), A/T (0.429), and T/T (0.228). 
From the NCBI SNP database, in European population, the fre-
quency of minor allele (A) of rs2661347 is 0.419 and that of major 
allele (T) is 0.581, and the genotype frequency is A/A (0.161), A/T 
(0.516), and T/T (0.323).5
snPs of the rgs4 and Transcription 
Factor Binding sites
Bioinformatics analysis found that SNPs 4, 7, and 18 are located 
in the binding sites for transcription factors within the putative 
promoter region of RGS4. The transcription factor binding sites 
in the regulatory sequence surrounding the SNPs were searched 
by using MatInspector in Genomatix.6 SNP4 is located in the 
predicted binding sites of Onecut homedomain factor hepatocyte 
nuclear factor-6 (HNF6) (matrix similarity was 0.960) and LEF1/
TCF (Matrix similarity was 0.887). The transcription factor HNF6 
is a transcriptional activator, which controls the expression of 
transcription factors and is expressed at early stages of liver and in 
neuronal differentiation (20). LEF1/TCF is a transcription factor 
in the Wnt signaling pathway, which functions by recruiting the 
5 http://www.ncbi.nlm.nih.gov/SNP/snp_ss.cgi?ss=ss51505122
6 http://www.genomatix.de
co-activator beta-catenin to the enhancer elements of target genes 
(21). LEF1/TCF is expressed in the hippocampus and is known to 
regulate the generation of dentate gyrus granule cells (22). LEF1/
TCF together with beta-catenin activates genes that play a role in 
the proliferation and differentiation of neuronal precursor cells. 
These transcription factors also regulate transcription of the 
Cav3.1 calcium channel gene in thalamic neurons of the adult 
mouse brain (23).
SNP7 is located in the binding sites of zinc finger protein of 
the cerebellum (Matrix similarity was 0.894). SNP18 is located in 
the binding sites of mouse Krüppel-like factor (Matrix similarity 
was 0.992) and nuclear factor of activated T-cells (NFAT) (Matrix 
similarity is 0.839). Zinc finger proteins such as Zac1 play a key 
role in the development of specific neuronal subsets in the cerebel-
lum (24). Krüppel-like factor (KLF) such as KLF7 acts as a tran-
scriptional activator and regulates development of dopaminergic 
neurons in the olfactory bulb (25). NFAT regulates transcription 
in NMDA receptor-stimulated cortical neurons (26).
absence of hypermethylation in the  
cpg islands of rgs4 in the DlPFc of  
scZ Patients
To study the methylation status of CpG islands of RGS4, all the 
105 DNA samples from the DLPFC of SCZ, NC, and BPD groups 
(35 in each group) from SMRI were bisulfite-treated, then PCR-
amplified and the amplified DNA fragments were sequenced. In 
every experiment with bisulfite treatment and sequencing of PCR 
products, methylated and non-methylated human DNA samples 
were included as positive and negative controls, respectively. 
Sequencing results showed that all the methylated Cs in treated 
methylated DNA samples remained unchanged, whereas all the 
Cs changed to Ts in all the treated non-methylated DNA samples. 
FigUre 7 | effects of haplotypes on RGS4-1 mrna expression. (a) Effect of haplotype 1(Hap1) on the mRNA expression of RGS4-1. The individuals with 
diplotype of two non-Hap1 have lower RGS4-1 mRNA expression level ( p = 0.0413). (B) In the SCZ group, non-Hap4 carriers have lower RGS4-1 mRNA 
expression level compared to those with non-Hap4 in NC ( p = 0.0192). Hap1 is CACCG, Hap4 is TTATA.
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However, no hypermethylation of CpG islands in the RGS4 gene 
was found in these samples. Therefore, hypermethylation of CpG 
islands in the regulatory region of RGS4 does not appear to be a 
causative factor for decreased mRNA expression level of RGS4-1 
observed in the DLPFC of SCZ patients.
DiscUssiOn
association of mrna expression of rgs4 
splice Variants with rgs4 snPs
Previously, we found that the mRNA expression level of the 
longest RGS4 isoform, RGS4-3 (which is now RGS4-1, according 
to the new nomenclature) was decreased in the DLPFC of SCZ 
patients (13). In the present study, to test the possible link 
between RGS4 SNPs and the decrease in RGS4 splice variants, 
we investigated the relationships of the genotypes, alleles, and 
haplotypes of the SNPs with the mRNA levels of RGS4 isoforms. 
Among the five isoforms, only RGS4-1 mRNA levels were asso-
ciated with these SNPs, but mRNA expression of other RGS4 
isoforms (RGS4-2 to RGS4-5) were not. The four SNPs associated 
with RGS4-1 mRNA levels are located in the 5′ regulatory region 
and therefore suggest a possible role for these SNPs in regulating 
RGS4-1 mRNA expression, which may have broader implica-
tions for RGS4 expression changes in other neuropsychiatric 
disorders (27) and drug addiction (28, 29). SNP18 is located in 
FigUre 8 | schematic representation of linkage disequilibrium (lD) 
between RGS4 snPs in the scZ, BPD, and nc groups. The LD block 
(thick black outline) consisting of four SNPs spans <1 kb (hence the 
Haploview program shows it as 0 kb). The number shown in each box in the 
figure corresponds to r2 which measures LD. r2 Values were calculated from 
the genotype data from the entire samples by Haploview. 1 = rs10917670 
(SNP1), 2 = rs2661347, 3 = rs951436(SNP4), 4 = rs951439(SNP7), 
5 = rs2661319(SNP18), 6 = rs10799897.
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the longest intron of the RGS4 gene and is in the binding site of 
the Krüppel-like transcription factor. Therefore, it is likely that 
this intron contains the regulatory elements that control RGS4-1 
mRNA expression.
We found that specific genotypes or alleles of SNPs of RGS4 
were associated with lower mRNA expression among the three 
groups. In the SCZ group, more individuals carry these risk alleles 
than in the NC group. The interaction of genotype and diagnosis 
was observed for SNP18. Some genotypes are associated with 
lower RGS4-1 mRNA levels in the SCZ group compared to NC. 
These lines of evidence suggest that there might be a genetic 
explanation for our previous finding of lower RGS4-1 mRNA 
level in the DLPFC of the SCZ group compared to the NC group 
(13). Since our sample size was not large, the results of our study 
need to be interpreted cautiously and additional future studies 
may be warranted. Nonetheless, our studies provide useful initial 
evidence for linking RGS4 mRNA expression to its SNPs similar 
to other such studies (30, 31).
For a number of tests in this study, we used Bonferroni adjust-
ment for pairwise comparison in each analysis. For example, to 
test the effect of SNP genotype on RGS4-1 expression, mRNA 
level was used as dependent factor, SNP genotype as independent 
variable and brain weight as covariate, and Bonferroni adjustment 
post hoc test was applied. We did not, however, perform further 
Bonferroni correction for multiple testing. This is because the six 
tested SNPs of RGS4 were not chosen randomly but were based 
on prior SNP association studies and their physical location in the 
5′ UTR and in the putative regulatory intronic regions of RGS4. In 
addition, these SNPs were in LD and the degree of independence 
between them was low. Moreover, the five splice variants of RGS4 
are not independent. Therefore, further correction for random 
effects would be extremely conservative and would result in a 
high type II error rate. The approach employed by us has been 
used before to investigate the relationship of SNPs of another SCZ 
candidate gene, Neuregulin 1 (32).
Another study (33) showed that RGS4 mRNA in the gray mat-
ter of DLPFC and the hippocampus in CBDB/NIMH collection 
and from Stanley collection did not change and none of the SNPs 
of RGS4 had a significant effect on RGS4 mRNA expression. As 
we discussed previously (13), judging by the PCR primers used 
in the Lipska et al. study, it appears that these authors detected 
combined mRNA expression of RGS4-1 to RGS4-4 but not that 
of RGS4-5. We, however, used RGS4-1 specific primers to detect 
its mRNA expression and found that it was associated with five 
individual SNPs or their haplotype or diplotype.
Three of the RGS4 SNPs (SNP4, SNP7 and SNP18) are located 
in the binding sites of transcriptional factors. It is possible that 
the SNP genotypes affect binding of transcription factors to the 
RGS4 cis-regulatory elements and thus affect RGS4-1 expression 
in DLPFC of SCZ. It is worth noting that the transcripts of other 
SCZ susceptibility genes such as PDLIM5, Neuregulin 1, and 
Neuregulin 3 were found to be associated with SNPs in their 
5′ regulatory regions and introns (32, 34, 35). SNP4 and SNP7 
are located around 6  kb upstream of the transcriptional start 
site 1 (TSS1) (Figure 1) and SNP18 is in intron 2 of RGS4 gene, 
which is close to putative TSS3. It is not clear whether these SNPs 
reside in the core promoter regions of RGS4. Thus far, the core 
promoter regions, cis-regulatory elements and the mechanisms 
of transcriptional regulation of RGS4 splice variants have not 
been identified clearly. Therefore, any functional studies on RGS4 
SNP variants must await full characterization of multiple RGS4 
promoters and other transcriptional regulatory mechanisms.
Others investigating Val158Met genotype of Catechol-O-
Methyl transferase (COMT) found that the carriers of the Val 
allele have significantly lower mRNA level of RGS4 than the 
subjects who were homozygous for the Met allele (33). Thus, 
polymorphism of other genes such as that of COMT likely affects 
RGS4 mRNA expression. It would be interesting to check whether 
the Val allele of COMT is associated with mRNA expression of a 
specific RGS4 splice variant.
rgs4 and scZ
The SNPs (SNP1, 4, 7, and 18) of RGS4 are associated with the 
clinical symptoms and antipsychotic treatment response in SCZ 
(8–10). Although there are some reports on lack of association 
between RGS4 and SCZ (36, 37), many studies have reported 
an association between RGS4 and SCZ (38, 39) and thus on 
balance, overall evidence is in favor of RGS4 as a susceptibility 
gene for SCZ. In this study, we found that the decrease of RGS4-1 
mRNA level was associated with a specific genotype or allele of 
the SNPs in the 5′ regulatory regions and intron 2 of the RGS4 
gene. Therefore, our findings support the notion that RGS4 SNPs 
might play a role in the etiology of SCZ through their influence 
on RGS4-1 mRNA expression.
How might RGS4 play a role in etiology of SCZ? One possibil-
ity is that RGS4 regulates glutamate signaling (40–42). Our stud-
ies (Ding et al., unpublished) showed that mouse Rgs4 regulates 
presynaptic calcium channels and synaptic transmission via its 
action on a G-protein interacting with metabotropic glutamate 
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receptors type 2. Others have interaction of Rgs4 with signaling 
by metabotropic glutamate receptors type 5 (43). Mouse Rgs4 has 
three different splice variants, which all encode the same protein 
containing 205 amino acids (aa). The human RGS4, however, has 
five splice variants of which RGS4-2 and RGS4-3 encode a 205 
aa protein similar to the mouse Rgs4. RGS4-1 shares the 205 aa 
region with the mouse Rgs4 but has extra 97 aa at the N-terminus. 
RGS4-5, on the other hand, lacks 18 N-terminal aa compared 
to the 205-aa protein encoded by RGS4-2 and RGS4-3 (12). 
Therefore, RGS4-1 protein might differentially regulate glutamate 
signaling compared to other RGS4 proteins.
RGS4 may also influence dopamine signaling and thus con-
tribute to SCZ pathology. RGS4 mRNA expression is associated 
with cortical dopamine signaling (33). The RGS4 N-terminal 
region can inhibit dopamine D2 and D3 receptor signaling (44) 
similar to other RGSs such as RGS9 (45). Therefore, RGS4-1 pro-
tein with its longer N-terminus might inhibit D2 and D3 receptor 
signaling and a decrease in RGS4-1 protein in the DLPFC of SCZ 
patients might cause an increase in D2 and D3 receptor signaling 
compared to normal subjects.
rgs4 and BPD
A previous case-control study (484 patients and 288 controls) 
showed significant association of SNP rs951436 with BPD thus 
supporting RGS4 as a potential BPD susceptibility gene (46). In 
another study, case-control comparisons revealed no significant 
differences for individual SNPs (SNP1, 4, 7, 18) between control 
and BPD, but an omnibus test in Brazil suggested differences in the 
overall distribution of haplotypes of all four SNPs (5). Previously, 
we found a trend toward lower RGS4-2 mRNA expression in 
the DLPFC of BPD patients (13). In the current study, however, 
we found that the mRNA ratio of RGS4-2 to RGS4-3 and that of 
RGS4-2 to RGS4-5 decreased in the BPD group compared to NC 
(p < 0.05). The ratio of RGS4-2 to other isoforms did not change. 
In addition, none of the RGS4 SNPs was found to be associated 
with mRNA level of RGS4-2 or with the ratio of RGS4-2 to RGS4-3 
or to RGS4-5 (p >  0.05). The decreases in ratios of RGS4-2 to 
RGS4-3 and to RGS4-5 hint at the possibility that RGS4 might 
have a role in the etiology of BPD.
cOnclUsiOn
The main finding of the present study is that levels of RG4-1 
mRNA are associated with SNPs in the regulatory region of the 
RGS4 gene. An additional finding is that the ratios of RGS4-2 to 
RGS4-3 and to RGS4-5 are decreased in PFC of BPD subjects rela-
tive to normal controls. A limitation of the study is the relatively 
small sample size. Future studies with larger sample sizes would 
be necessary to confirm our observations.
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